Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706780 | 0.75 | MAOB (0.37) | — | |
| SCHEMBL2123339 | 0.65 | MAOA (0.41) | NPC1RAB9A | |
| SCHEMBL19629987 | 0.65 | MAOB (0.39) | NPC1RAB9A | |
| SCHEMBL10285185 | 0.65 | EPHX2 (0.50) | NPC1RAB9A | |
| SCHEMBL2797763 | 0.63 | MAOB (0.40) | NPC1RAB9A | |
| SCHEMBL23781329 | 0.62 | HTT (0.46) | NPC1RAB9A | |
| SCHEMBL13356540 | 0.62 | MAOB (0.45) | NPC1RAB9A | |
| SCHEMBL2925433 | 0.62 | HTT (0.56) | NPC1RAB9A | |
| SCHEMBL13356496 | 0.62 | MAOB (0.39) | NPC1RAB9A | |
| SCHEMBL25110146 | 0.62 | KMT2A (0.43) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | GLAXO GROUP LIMITED (GB) | 2010-10-07 | — | — | US | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | NPC1 304/4885RAB9A 1510/4885 |
| US-20100256124-A1 | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials | TOP1, TOP2A, NDC1 | NPC1 610/4885RAB9A 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.